Clinical Trial Update: Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial evaluating SGI-110 with irinotecan versus regorafenib or TAS-102 in previously treated metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Regorafenib (regorafenib)
• SGI-110 with irinotecan
• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Previously Treated Metastatic Colorectal Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-09-14